Phaseline

Companies › Mesoblast

Mesoblast: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rexlemestrocel-L + HA
Mesenchymal stem cells (allogeneic bone marrow-derived) combined with hyaluronic acid
–Phase 3Degenerative Disc DiseaseJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06325566Rexlemestrocel-L + HAPhase 3Degenerative Disc DiseaseOtherJul 2027

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

ROKIT Healthcare Aesculap Biologics Metcela OHB Pediatrics CoNextions Medical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.